Alluvi Reta Pen | BPC-157 & TB-500
Alluvi Reta Pen, BPC-157 & TB-500. Alluvi Retatrutide, BPC-157, and TB-500 (40 mg) are research-grade substances that are only provided for use in laboratories and research and development; they are not intended for use by humans or animals. While BPC-157 and TB-500 are peptides frequently examined for tissue repair and recovery, retatrutide is a GLP-1 multi-agonist studied for weight loss. BPC-157 & TB-500 40mg
- Type: GLP-1/GIP/GCGR multi-agonist peptide.
- Research Goals: Examined for weight loss, appetite management, and metabolic control.
- Results: Using high-dose regimens, clinical studies have demonstrated an average weight loss of 18.3 kg over 48 weeks, with some patients experiencing a reduction of up to 22.5%.
- Mechanism: Reduces calorie intake without enforced dieting by improving satiety signals.
- Formulation: Provided in pre-filled 20 mg or 40 mg pens for controlled laboratory investigation of delivery systems and compound stability.
- Important Note: Only for research and development; not authorized for therapeutic use.
Alluvi Reta Pen | TB-500 and BPC-157 (40 mg Combination)
- Type: Blend of peptides (20 mg BPC-157 + 20 mg TB-500).
- Research Goals: Examined for skin elasticity, bone strength, tendon healing, and joint support.
- Formulation: Provided in a 40 mg pre-filled pen kit that is sealed for assessment of the injection method and compound stability.
- Storage: Do not freeze; refrigerate between 2 and 8°C.
- Administration (R&D context): For controlled trials, pens enable dosage adjustments in increments of 2.5 mg or 5 mg.
- Important Note: This formulation is not intended for human or veterinary use, just like retatrutide.
Alluvi Reta Pen | Comparison Table
| Compound | Type/Category | Primary Research Focus | Dosage Form | Key Findings |
|---|---|---|---|---|
| Retatrutide | GLP-1 multi-agonist | Weight loss, metabolic control | 20mg / 40mg pens | Up to 22.5% weight reduction in trials |
| BPC-157 | Peptide | Tissue repair, gut healing | 20mg (part of combo) | Studied for tendon/ligament recovery |
| TB-500 | Peptide | Muscle & tissue recovery | 20mg (part of combo) | Investigated for wound healing, repair |
Risks and Restrictions
- Unapproved for medical use: These substances are solely provided for research and development and shouldn’t be applied to people or animals.
- Potential abuse: Off-label use may be tempted by online availability; however, there are unknown safety hazards involved.
- Regulatory status: BPC-157 and TB-500 are not FDA-approved medications, while retatrutide is still under research.
Important Takeaway
Alluvi’s advanced peptide formulations, BPC-157/TB-500 40 mg and Retatrutide 40 mg, are intended for controlled laboratory studies on tissue repair and weight control. Although preliminary research indicates encouraging outcomes in terms of weight loss and recuperation, it is still purely experimental and not meant for human consumption. BPC-157 & TB-500 40mg
Be the first to review “BPC-157 & TB-500 40mg”
Related products
Alluvi Retatrutide
Alluvi Retatrutide
Alluvi Retatrutide
Alluvi Retatrutide
Alluvi Retatrutide
Reviews
There are no reviews yet.